MeRT TMS for PTSD: Everything You Need To Know

In June 2026, the FDA cleared a brand new type of Transcranial Magnetic Stimulation for PTSD called Magnetic EEG-Guided Resonance Therapy (MeRT). Not only is this the first type of TMS cleared for PTSD in the United States, but it’s also the first type of TMS that uses EEG guidance to personalize the treatment protocols.

While TMS providers have treated PTSD with TMS for 20+ years, this has almost always been off-label, using protocols lifted from depression research or experimenting with novel protocols.

What is MeRT, how does it work, and what does the clearance actually change for the patients, clinics, and insurance companies?

Can a patient with dreadlocks do TMS?

MeRT is not necessarily a new TMS machine. It’s more like an additional layer on top of your existing TMS machine–although as of writing this in July 2026, MagVenture is the only company currently compatible with MeRT. This additional layer acts as both an imaging system and a treatment recommendation engine that spits out a TMS protocol based on the imaging.

It works like this: before a TMS treatment session begins, the patient sits for a short resting state EEG while they keep their eyes closed. After the recording is completed, it’s automatically sent to Wave Neuroscience’s cloud platform, where the recording is compared to a normative database of hundreds of thousands of EEGs, and then analyzed statistically–a process known as a quantitative EEG (qEEG). An AI-assisted analysis flags neural anomalies, and then creates an extraordinarily personalized protocol recommendation that involves treatment location, power levels, frequencies, and augmentations.

Once the TMS provider (or technician, especially in the case of subsequent sessions) reviews the recommendations, they simply input them into the TMS device and run the session. The benefit of this approach is that TMS providers don’t need to become clinical neuroscientists in order to provide personalized TMS therapy; rather, a TMS provider can simply trust the MeRT algorithm for recommendations.

In contrast, non-MeRT TMS therapy can still be personalized using fMRI imaging, MRI imaging, or simply using symptoms to guide protocol adjustments. However, all of these approaches have their unique benefits and trade-offs in comparison to MeRT. For example, MRI machines are expensive, add to the total cost of care, and outside of a university or hospital system, require a referral and a smooth third-party hand-off to the imaging facility. In a symptom-based personalized technique (which is included in Solstice Training Institute’s Provider course), brain imaging data isn’t even referred to when deciding which TMS protocols are appropriate.

What Science Tells Us About EEG Guided TMS

As qEEG is highly sensitive to change, there is definitely a consensus that TMS modulates the EEG/qEEG, meaning that TMS modulates the brain’s electrical activity. How TMS exactly modulates this activity is not yet known. Wischnewski et al(2024) showed with experimental data that TMS can successfully modulate the mu rhythm in the brain. Otherwise, TMS seems to primarily impact phase and functional connectivity metrics much moreso than power. A recent review from Stango et al(2025) shows that TMS can certainly impact underlying neurophysiology, but the science isn’t particularly clear on the empirical link between mood, electroneurophysiology, and TMS parameters just yet.

What Science Tells Us About TMS for PTSD

There is a relatively long history of using TMS to treat refractory PTSD. Many studies on TMS for Major Depressive Disorder also included a cohort of patients with comorbid PTSD. Other studies have specifically looked at treating PTSD as a solo diagnosis, and the protocol choices typically range between the LDLPFC or the RDLPFC in the hope of targeting the salience network or anxiosomatic network using intermittent theta burst stimulation or continuous theta burst stimulation.

A recent meta-analysis by Wang et al (2025) showed that TMS was a helpful intervention for PTSD. It also showed that there doesn’t seem to be a clear winner just yet in terms of protocol choice - it seems that LDLPFC works for some, RDLPFC works for some, and either may be just fine. In fact, there is even updated research from Isserless et al (2021) that dTMS can help treat PTSD using the H1 coil, which targets both the LDLPFC and RDLPFC by using an excitatory frequency. Similarly, there was little clarity on high frequency TMS compared to low frequency TMS, which makes a great case for MeRT given the uncertainty on best practices at the moment.

Furthering this research, we also know with relative certainty that PTSD has a clear electrical biomarker. GrayMatters Health, the medical device company that developed Prism neurofeedback, used this biomarker in a device that was FDA cleared in Q1 of 2023.

What the Results Show for PTSD

What moved the FDA into action was much larger than what the previous studies illustrated. This was a double-blind, randomized, sham-controlled trial across multiple sites, run with investigators at Texas A&M. This study showed statistically significant and clinically meaningful drops in PTSD symptom severity against a sham control.

Endpoint reductions in core PTSD symptom severity on standardized clinician rated scales, helped carry the FDA’s decision. The study reported sleep quality improvements, which means a lot given how central sleep wreckage is to PTSD. It also showed EEG markers shifting back toward normal, which lines up with the targeting mechanism.

Can TMS Clinics Bill For MeRT?

The distance between "FDA-cleared" and "the payer pays" is large.

The TMS codes haven't changed. You've got 90867 for the initial session with motor threshold determination, billed once per course. 90868 for subsequent delivery. 90869 for a subsequent session where you re-determine the motor threshold. A standard course runs 36 to 50 sessions. For covered indications, Medicare's 2026 national average for the planning code sits in the low hundreds, with per-session delivery paying less, and commercial rates are all over the map.

So far, all of this coverage is built around depression, not PTSD. Payer policies tie TMS reimbursement to Major Depressive Disorder, F32.2 or F33.2, usually demanding two failed antidepressant trials and prior authorization. Even though OCD has been cleared since 2018, many payers still have yet to catch up in terms of writing their own coverage policies. As of writing this, TMS for PTSD has no written coverage policy yet. This means that, almost all of the time, a provider will have to request a prior authorization, understand that it will result in an initial denial, and then fight the denial in a peer to peer review.

There's also no CPT code for the EEG personalization itself. The qEEG falls under separate EEG coding which is currently considered not medically necessary for PTSD, and generating the individualized protocol isn't separately reimbursed. Right now the personalization is clinical value that doesn’t generate incremental billable revenue.

Clearance does start the clock for payers to create and review their medical necessity policies, but that clocks can take years. So in 2026, treat MeRT for PTSD as a cash-pay or hybrid offering for most patients, unless you’re willing to fight tooth-and-nail in a peer to peer review on a case by case basis (which would not be a bad strategy by any means). Plenty of TMS practices already run depression TMS through insurance while offering Spravato, ketamine, and SGB on self-pay or partial coverage. 

What This Means for Technicians and Practices

Competency now covers two layers. Delivering MeRT well takes everything a strong technician already does (including accurate coil placement, solid motor threshold technique, adequate documentation, and a focus on patient comfort and monitoring), but adds the EEG work top. A great TMS Technician and MeRT means that you’ve built a hyper-responsive clinic. However, a poor TMS Technician with sloppy recording technique could theoretically botch the qEEG and input bad data into the algorithm. If anything, this development makes choosing and training your TMS Technicians more important than ever.

The natural front line is first responders and Veterans. They carry the heaviest PTSD burden, and a labeled, non-invasive, drug-free option lands with them. If you serve those communities, expect the questions, and be ready to answer them accurately–including all of the coverage caveats explained above.

What Next for MeRT in the Real World?

MeRT's clearance is the first time a personalized, EEG-guided TMS system has carried a PTSD indication. Because of their landmark study, we have a better understanding that matching stimulation to a person's own brain activity might matter more than we originally thought, especially in disorders as heterogeneous as PTSD.

If you're weighing where personalized neuromodulation fits into your trauma or TMS company, it’s certainly worth considering MeRT–as long as you understand the billing and operational complexities involved to do it well.